Nature Communications (Jan 2021)
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
- Yao Wang,
- Chuan Tong,
- Hanren Dai,
- Zhiqiang Wu,
- Xiao Han,
- Yelei Guo,
- Deyun Chen,
- Jianshu Wei,
- Dongdong Ti,
- Zongzhi Liu,
- Qian Mei,
- Xiang Li,
- Liang Dong,
- Jing Nie,
- Yajing Zhang,
- Weidong Han
Affiliations
- Yao Wang
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Chuan Tong
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Hanren Dai
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Zhiqiang Wu
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Xiao Han
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Yelei Guo
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Deyun Chen
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Jianshu Wei
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Dongdong Ti
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Zongzhi Liu
- Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences
- Qian Mei
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Xiang Li
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Liang Dong
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Jing Nie
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- Yajing Zhang
- Department of Bio-therapeutic, the First Medical Centre, Chinese People’s Liberation Army General Hospital
- Weidong Han
- Department of Molecular Biology and Immunology, Institute of Basic Medicine, Chinese People’s Liberation Army General Hospital
- DOI
- https://doi.org/10.1038/s41467-020-20696-x
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
De novo DNA methylation has been associated with T cell exhaustion in cancer immunotherapy. Here the authors show that the pre-treatment of CD19 CAR-T cells with the DNA methyltransferase inhibitor decitabine limits exhaustion and confers enhanced proliferative, effector and memory properties upon antigen exposure, with improved tumor control.
